Research programme: monoclonal antibodies - ImmunoCellular Therapeutics

Drug Profile

Research programme: monoclonal antibodies - ImmunoCellular Therapeutics

Alternative Names: ICT-037; ICT-109; ICT-169; ICT-37; ICT-69; ICT-Diagnostic-SCLC

Latest Information Update: 01 Aug 2013

Price : $50

At a glance

  • Originator ImmunoCellular Therapeutics
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Colorectal cancer; Multiple myeloma; Ovarian cancer; Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 01 Aug 2013 Preclinical development is ongoing in USA
  • 02 Jun 2011 ImmunoCellular Therapeutics in-licenses the Potelligent® antibody technology platform from BioWa
  • 06 Jan 2011 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top